治疗干眼症新药lifitegrast

Lifitegrast,a novel drug for the treatment of dry eye disease

lifitegrast是一种新型小分子T细胞抑制剂,通过影响细胞粘附分子(ICAM-1)与淋巴细胞功能相关抗原(LFA-1)的结合,有效阻断炎症通路,抑制T细胞介导的炎症反应,从而改善干眼症患者的症状与体征。多项动物试验及临床研究显示,lifitegrast具有良好的安全性和耐受性。2016年7月美国FDA批准其上市,用于干眼症的治疗。本文对其药理作用、药动学、临床研究及安全性等进行综述。

Lifitegrast is a novel small T-cell inhibitor, which targets the inflammatory pathways involved in the dry eye disease （DED） by blocking the binding of intercellular adhesion molecule （ ICAM-1 ） to the integrin lymphocyte function-associated antigen 1 （LFA-1） and inhibiting T cell-mediated inflammation associated with DED. Lifitegrast is a prospective drug for the treatment of DED, demonstrating a dose-dependent response in the relieving of both signs and symptoms. In Vitro assays and in vivo studies showed that lifitegrast is well tolerated and has mild side effects. Lifitegrast has been approved by FDA in July 2016. We summarized its pharmacological effect, pharmacokinetics, clinical use and safety in this article.